← All Signals

🏥 FDA: The Harvard Drug Group LLC — Class II

healthcareneutralSource: FDA
80%Confidence
0Views
FDASource
2026-03-23Date

Summary

Harvard Drug Group's packaging defect for Midodrine tablets reveals potential supply chain quality issues in blister packaging operations. This could affect patient medication integrity and lead to temporary supply shortages for this blood pressure medication.

Actionable: Monitor Midodrine Hydrochloride tablet availability and consider temporary alternative sourcing if this medication is critical to operations.

AI Confidence: 80%

Data Points

firmThe Harvard Drug Group LLC
classificationClass II
statusOngoing
distributionNationwide US.
productMidodrine Hydrochloride Tablets, USP, 5 mg, 50 Tablets (5 x 10 blister packs), Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapol

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now